Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

News

Conference Coverage
Sunvozertinib Shows Promise Among Patients With Platinum Pre-Treated Non-Small Cell Lung Cancer Harboring EGFR Mutations
06/20/2024

Stephanie Holland

Stephanie Holland
Primary analysis results from the phase 2 WU-KONG1 study found that sunvozertinib demonstrated promising anti-tumor efficacy and safety among patients with platinum pre-treated locally advanced or metastatic non-small cell lung cancer...
Primary analysis results from the phase 2 WU-KONG1 study found that sunvozertinib demonstrated promising anti-tumor efficacy and safety among patients with platinum pre-treated locally advanced or metastatic non-small cell lung cancer...
Primary analysis results from...
06/20/2024
Oncology
Suresh Ramalingam, MD
Conference Coverage
Concurrent Osimertinib Improved PFS Among Patients With Unresectable, Stage 3 EGFR-Mutated Non-Small Cell Lung Cancer
06/02/2024
Suresh Ramalingam, MD
Suresh Ramalingam, MD, discussed results from the phase 3 LAURA study which demonstrated that administration of osimertinib following definitive chemoradiation improved PFS among patients with unresectable, stage 3, EGFR-mutated NSCLC.
Suresh Ramalingam, MD, discussed results from the phase 3 LAURA study which demonstrated that administration of osimertinib following definitive chemoradiation improved PFS among patients with unresectable, stage 3, EGFR-mutated NSCLC.
Suresh Ramalingam, MD, discussed...
06/02/2024
Oncology

Advertisement

Natasha Leighl, MD
Conference Coverage
Subcutaneous vs Intravenous Amivantamab Plus Lazertinib for Patients With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
06/01/2024
Natasha Leighl, MD
Natasha Leighl, MD, discussed results from the phase 3 PALOMA-3 trial which compared subcutaneous and intravenous amivantamab plus lazertinib in patients with advanced, EGFR-mutated non-small cell lung cancer.
Natasha Leighl, MD, discussed results from the phase 3 PALOMA-3 trial which compared subcutaneous and intravenous amivantamab plus lazertinib in patients with advanced, EGFR-mutated non-small cell lung cancer.
Natasha Leighl, MD, discussed...
06/01/2024
Oncology
News
First-Line Osimertinib for Patients With Metastatic NSCLC Harboring Uncommon EGFR Mutations
12/12/2023

Stephanie Holland 

Stephanie Holland 
Results from the nonrandomized, phase 2 UNICORN trial demonstrated that first-line osimertinib is a clinically effective and safe treatment option for patients with metastatic non-small cell lung cancer harboring an uncommon EGFR mutation.
Results from the nonrandomized, phase 2 UNICORN trial demonstrated that first-line osimertinib is a clinically effective and safe treatment option for patients with metastatic non-small cell lung cancer harboring an uncommon EGFR mutation.
Results from the nonrandomized,...
12/12/2023
Oncology
Nicolas Girard, MD, Institut Curie
Videos
PAPILLON Trial Establishes Amivantamab Plus Chemotherapy as New First-Line Standard of Care in EGFR Exon 20 Insertion-Mutated Advanced NSCLC
10/23/2023

Featuring Nicolas Girard, MD

Featuring Nicolas Girard, MD
Prof Nicolas Girard, MD, discusses primary results from the phase 3 PAPILLON study comparing amivantamab plus chemotherapy vs chemotherapy alone for the first-line treatment of patients with EGFR exon 20 insertion-mutated advanced NSCLC.
Prof Nicolas Girard, MD, discusses primary results from the phase 3 PAPILLON study comparing amivantamab plus chemotherapy vs chemotherapy alone for the first-line treatment of patients with EGFR exon 20 insertion-mutated advanced NSCLC.
Prof Nicolas Girard, MD,...
10/23/2023
Oncology

Advertisement

Nicolas Girard, MD, Institut Curie
Videos
PAPILLON Trial Establishes Amivantamab Plus Chemotherapy as New First-Line Standard of Care in EGFR Exon 20 Insertion-Mutated Advanced NSCLC
10/23/2023

Featuring Nicolas Girard, MD

Featuring Nicolas Girard, MD
Prof Nicolas Girard, MD, discusses primary results from the phase 3 PAPILLON study comparing amivantamab plus chemotherapy vs chemotherapy alone for the first-line treatment of patients with EGFR exon 20 insertion-mutated advanced NSCLC.
Prof Nicolas Girard, MD, discusses primary results from the phase 3 PAPILLON study comparing amivantamab plus chemotherapy vs chemotherapy alone for the first-line treatment of patients with EGFR exon 20 insertion-mutated advanced NSCLC.
Prof Nicolas Girard, MD,...
10/23/2023
Oncology
News
Patritumab Deruxtecan for Patients With Previously Treated, EGFR-Mutated Non-Small Cell Lung Cancer
10/18/2023

Stephanie Holland 

Stephanie Holland 
Results from the phase 2 HERTHENA-Lung01 trial found that patritumab deruxtecan is clinically durable and effective for patients with previously treated EGFR-mutated NSCLC.
Results from the phase 2 HERTHENA-Lung01 trial found that patritumab deruxtecan is clinically durable and effective for patients with previously treated EGFR-mutated NSCLC.
Results from the phase 2...
10/18/2023
Oncology
News
Amivantamab Plus Chemotherapy Provides PFS Benefit in EGFR-Mutated NSCLC
09/11/2023

Stephanie Holland 

Stephanie Holland 
According to Janssen Pharmaceutical Companies of Johnson & Johnson, amivantamab with or without lazertinib plus chemotherapy significantly improves progression-free survival among patients with EGFR-mutated NSCLC.
According to Janssen Pharmaceutical Companies of Johnson & Johnson, amivantamab with or without lazertinib plus chemotherapy significantly improves progression-free survival among patients with EGFR-mutated NSCLC.
According to Janssen...
09/11/2023
Oncology

Advertisement

News
Amivantamab Plus Chemotherapy Provides PFS Benefit in EGFR-Mutated NSCLC
09/11/2023

Stephanie Holland 

Stephanie Holland 
According to Janssen Pharmaceutical Companies of Johnson & Johnson, amivantamab with or without lazertinib plus chemotherapy significantly improves progression-free survival among patients with EGFR-mutated NSCLC.
According to Janssen Pharmaceutical Companies of Johnson & Johnson, amivantamab with or without lazertinib plus chemotherapy significantly improves progression-free survival among patients with EGFR-mutated NSCLC.
According to Janssen...
09/11/2023
Oncology
News
Lazertinib as Another First-Line Option for Patients With EGFR-Mutated, Advanced NSCLC
08/02/2023

Stephanie Holland

Stephanie Holland
According to results from the phase 3 LASER301 trial, lazertinib significantly improved efficacy compared to gefitinib among patients with treatment-naïve EGFR-mutated advanced NSCLC, with a manageable safety profile.
According to results from the phase 3 LASER301 trial, lazertinib significantly improved efficacy compared to gefitinib among patients with treatment-naïve EGFR-mutated advanced NSCLC, with a manageable safety profile.
According to results from the...
08/02/2023
Oncology

Advertisement

Advertisement

Advertisement

Recent News

FDA Alerts
FDA Approves Zolbetuximab Plus Chemotherapy for Patients With HER2-Negative Gastric/Gastroesophageal Junction Adenocarcinoma With CLDN18.2-Positive Tumors
10/18/2024
Based on results from the SPOTLIGHT and GLOW trials, the FDA has approved first-line zolbetuximab plus fluoropyrimidine and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-negative gastric...
Based on results from the SPOTLIGHT and GLOW trials, the FDA has approved first-line zolbetuximab plus fluoropyrimidine and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-negative gastric...
Based on results from the...
10/18/2024
Oncology
Conference Coverage
First-Line Abemaciclib Plus Endocrine Therapy Improves Efficacy Among Patients With HR-Positive, HER2-Negative Advanced Breast Cancer
10/18/2024
Results from the phase 2 ABIGAIL trial demonstrated that first-line abemaciclib plus endocrine therapy improves efficacy compared to standard chemotherapy among patients with HR-positive, HER2-negative advanced breast cancer.
Results from the phase 2 ABIGAIL trial demonstrated that first-line abemaciclib plus endocrine therapy improves efficacy compared to standard chemotherapy among patients with HR-positive, HER2-negative advanced breast cancer.
Results from the phase 2 ABIGAIL...
10/18/2024
Oncology
FDA Approval
FDA Approves Tumor Treating Fields Wearable Device for Patients With Metastatic Non-Small Cell Lung Cancer
10/17/2024
On October 15, 2024, the FDA granted approval to the Optune Lua, a wearable device that delivers Tumor Treating Fields, for treatment of patients with metastatic non-small cell lung cancer.
On October 15, 2024, the FDA granted approval to the Optune Lua, a wearable device that delivers Tumor Treating Fields, for treatment of patients with metastatic non-small cell lung cancer.
On October 15, 2024, the FDA...
10/17/2024
Oncology
News
Treatment With 131L-Apamistamab Before AlloHCT Demonstrates Efficacy, Safety Among Older Patients With R/R AML
10/15/2024
According to phase 3 results from the SIERRA trial, anti-CD45 radioconjugate 131I-apamistamab was well-tolerated and showed a higher durable complete remission rate than standard care among older patients with relapsed/refractory acute...
According to phase 3 results from the SIERRA trial, anti-CD45 radioconjugate 131I-apamistamab was well-tolerated and showed a higher durable complete remission rate than standard care among older patients with relapsed/refractory acute...
According to phase 3 results...
10/15/2024
Oncology
FDA Approval
FDA Approves Inavolisib, With Palbociclib and Fulvestrant, for Endocrine-Resistant, PIK3CA-Mutated, HR-Positive, HER2-Negative Advanced Breast Cancer
10/10/2024
The FDA has approved inavolisib, with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.
The FDA has approved inavolisib, with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.
The FDA has approved inavolisib,...
10/10/2024
Oncology
News
Momelotinib Demonstrates Improved Spleen and Symptom Requirements Among Subgroup of Patients With JAK Inhibitor-Naive Myelofibrosis
10/10/2024
Momelotinib was well-tolerated, improved spleen and symptom responses, and reduced transfusion burden among a subgroup of patients with JAK inhibitor-naive myelofibrosis, determined an analysis of the phase 3 SIMPLIFY-1 study.
Momelotinib was well-tolerated, improved spleen and symptom responses, and reduced transfusion burden among a subgroup of patients with JAK inhibitor-naive myelofibrosis, determined an analysis of the phase 3 SIMPLIFY-1 study.
Momelotinib was well-tolerated,...
10/10/2024
Oncology
News
Nivolumab, Pomalidomide, and Elotuzumab Combination for Patients With R/R Multiple Myeloma
10/10/2024
Nivolumab plus pomalidomide and dexamethasone plus or minus elotuzumab did not demonstrate a clinical benefit compared with pomalidomide and dexamethasone treatment for patients with relapsed/refractory multiple myeloma, according to phase 3...
Nivolumab plus pomalidomide and dexamethasone plus or minus elotuzumab did not demonstrate a clinical benefit compared with pomalidomide and dexamethasone treatment for patients with relapsed/refractory multiple myeloma, according to phase 3...
Nivolumab plus pomalidomide and...
10/10/2024
Oncology
News
Evaluating Long-Term Efficacy and Safety of AlloSCT Among Patients With Peripheral T-Cell Lymphoma
10/10/2024
While allogeneic stem cell transplantation is the preferred treatment for younger, transplant-eligible patients with relapsed/refractory peripheral T-cell lymphoma, it is currently not recommended as part of first-line consolidation,...
While allogeneic stem cell transplantation is the preferred treatment for younger, transplant-eligible patients with relapsed/refractory peripheral T-cell lymphoma, it is currently not recommended as part of first-line consolidation,...
While allogeneic stem cell...
10/10/2024
Oncology
News
Neo/Adjuvant Pembrolizumab Significantly Improves Overall Survival for Patients With Early-Stage Triple-Negative Breast Cancer
10/09/2024
According to results from the phase 3 KEYNOTE-522 trial, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab significantly improved overall survival among patients with early-stage triple-negative breast cancer.
According to results from the phase 3 KEYNOTE-522 trial, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab significantly improved overall survival among patients with early-stage triple-negative breast cancer.
According to results from the...
10/09/2024
Oncology
Conference Coverage
Optimal Ifinatamab Deruxtecan Dose for Patients With Heavily Pretreated Extensive-Stage Small Cell Lung Cancer
10/09/2024
According to interim analysis results from the ongoing phase 2 IDeate-Lung01 trial, 12 mg/kg of ifinatamab deruxtecan is preferable to 8 mg/kg among patients with heavily pretreated extensive-stage small cell lung cancer.
According to interim analysis results from the ongoing phase 2 IDeate-Lung01 trial, 12 mg/kg of ifinatamab deruxtecan is preferable to 8 mg/kg among patients with heavily pretreated extensive-stage small cell lung cancer.
According to interim analysis...
10/09/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use